A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis

Moderate and Severe Rheumatoid Arthritis Clinical Trial

Official title: A Phase II, Placebo-Controlled, Multicenter, Dynamic Randomized, Double Blind Trial of RC18, a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein in Subjects With Inadequate Response of TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis

Status Terminated

Clinical Trial Summary

This is a phase Ⅱ, placebo-controlled, multicenter, dynamic randomized, double blind study of the efficacy and safety of RC18, a recombinant human B lymphocyte stimulating factor receptor-antibody fusion protein in subjects with inadequate response of TNF-α antagonists due to treat moderate and severe rheumatoid arthritis.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Moderate and Severe Rheumatoid Arthritis

• NCT number: NCT02882087
• Study type: Interventional
• Source: RemeGen
• Status: Terminated
• Phase: Phase 2
• Start date: October 2015
• Completion date: February 25, 2019